CN104119349B - 二氢埃托啡及其制备 - Google Patents

二氢埃托啡及其制备 Download PDF

Info

Publication number
CN104119349B
CN104119349B CN201410312065.XA CN201410312065A CN104119349B CN 104119349 B CN104119349 B CN 104119349B CN 201410312065 A CN201410312065 A CN 201410312065A CN 104119349 B CN104119349 B CN 104119349B
Authority
CN
China
Prior art keywords
formula
test
compound
dosing
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410312065.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104119349A (zh
Inventor
史蒂夫·怀特洛克
德博拉·菲莉丝·哈丁
卡尔·戴维·特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104119349(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0822342A external-priority patent/GB0822342D0/en
Priority claimed from GB0920699A external-priority patent/GB0920699D0/en
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CN104119349A publication Critical patent/CN104119349A/zh
Application granted granted Critical
Publication of CN104119349B publication Critical patent/CN104119349B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201410312065.XA 2008-12-08 2009-12-04 二氢埃托啡及其制备 Expired - Fee Related CN104119349B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0822342A GB0822342D0 (en) 2008-12-08 2008-12-08 Dihydroetorphine
GB0822342.2 2008-12-08
GB0920699A GB0920699D0 (en) 2009-11-26 2009-11-26 Dihydroetorphine
GB0920699.6 2009-11-26
CN200980156324.1A CN102307877B (zh) 2008-12-08 2009-12-04 二氢埃托啡及其制备

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980156324.1A Division CN102307877B (zh) 2008-12-08 2009-12-04 二氢埃托啡及其制备

Publications (2)

Publication Number Publication Date
CN104119349A CN104119349A (zh) 2014-10-29
CN104119349B true CN104119349B (zh) 2017-04-12

Family

ID=42046251

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410312065.XA Expired - Fee Related CN104119349B (zh) 2008-12-08 2009-12-04 二氢埃托啡及其制备
CN200980156324.1A Expired - Fee Related CN102307877B (zh) 2008-12-08 2009-12-04 二氢埃托啡及其制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980156324.1A Expired - Fee Related CN102307877B (zh) 2008-12-08 2009-12-04 二氢埃托啡及其制备

Country Status (31)

Country Link
US (4) US20120010231A1 (enExample)
EP (2) EP2370443B1 (enExample)
JP (2) JP5787764B2 (enExample)
KR (2) KR101992272B1 (enExample)
CN (2) CN104119349B (enExample)
AR (1) AR074545A1 (enExample)
AU (1) AU2009326196B2 (enExample)
CA (1) CA2745537C (enExample)
CL (1) CL2011001363A1 (enExample)
CY (1) CY1116875T1 (enExample)
DK (1) DK2370443T3 (enExample)
EA (1) EA022210B1 (enExample)
ES (1) ES2548881T3 (enExample)
HR (1) HRP20151138T1 (enExample)
HU (1) HUE025913T2 (enExample)
IL (1) IL213207B (enExample)
ME (1) ME02262B (enExample)
MX (2) MX2011006095A (enExample)
MY (1) MY159913A (enExample)
NZ (1) NZ593102A (enExample)
PA (1) PA8852801A1 (enExample)
PL (1) PL2370443T3 (enExample)
PT (1) PT2370443E (enExample)
RS (1) RS54309B1 (enExample)
SG (1) SG171456A1 (enExample)
SI (1) SI2370443T1 (enExample)
SM (1) SMT201500273B (enExample)
TW (2) TWI541246B (enExample)
UY (1) UY32295A (enExample)
WO (1) WO2010067101A1 (enExample)
ZA (1) ZA201104161B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
MX2015008624A (es) 2012-12-31 2016-12-08 Rhodes Tech PROCESO PARA PREPARAR 6A, 14A-ETENOMORFINANOS 7ß SUSTITUIDOS Y 6A, 14A-ETANOMORFINANOS 7ß-SUSTITUIDOS.
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3023427A1 (en) 2014-11-19 2016-05-25 Siegfried AG Improved method of manufacturing buprenorphine and analogues thereof from oripavine
EP3067357A1 (en) * 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
GB201513441D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal delivery system
GB201513442D0 (en) * 2015-07-30 2015-09-16 Euro Celtique Sa Transdermal patch
CN114105875B (zh) * 2021-12-06 2023-11-03 四川大学 一种吗啡衍生物二氢埃托啡的合成方法
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168377A (zh) * 1996-05-28 1997-12-24 东国制药株式会社 新的丁丙诺菲止痛剂同型物
WO2008109156A2 (en) * 2007-03-06 2008-09-12 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
JPS59184182A (ja) 1983-04-02 1984-10-19 Res Inst For Prod Dev ３−ベンゾイルチオ−４、５α−エポキシ−７α−〔１（Ｒ）−ヒドロキシ−１−メチルベンチル〕−６−メトキシ−１７−メチル−６、１４−エンド−エタノモルヒナン
JPS62153214A (ja) 1985-12-26 1987-07-08 Nitto Electric Ind Co Ltd 医薬製剤
JPS62281815A (ja) 1986-05-27 1987-12-07 Teisan Seiyaku Kk 貼付剤及びその製造法
JPS63201119A (ja) 1987-02-17 1988-08-19 Kao Corp 貼付剤組成物
US4891377A (en) 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
WO1994006426A1 (en) 1992-09-21 1994-03-31 Qin Bo Yi Methods for identifying and using low/non-addictive opioid analgesics
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
CZ292151B6 (cs) 1995-06-07 2003-08-13 Ortho-Mcneil Pharmaceutical, Inc. Transdermální náplast pro podávání 17-deacetylnorgestimátu samotného nebo v kombinaci s estrogenem
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
DE69942928D1 (de) 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
DE60143477D1 (de) 2000-04-26 2010-12-30 Watson Pharmaceuticals Inc Verminderung der nebenwirkungen bei der oxybutynin-therapie
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
MXPA02003670A (es) 2000-07-13 2003-01-28 Euro Celtique Sa Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AU2002322169B2 (en) 2001-08-10 2008-10-30 Monash University Derivatives of morphine-like opioid compounds
CN1233645C (zh) * 2001-09-14 2005-12-28 中国人民解放军军事医学科学院毒物药物研究所 新的东罂粟碱衍生物及其医药用途
US20040024005A1 (en) 2002-01-23 2004-02-05 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
CA2487123C (en) 2002-05-28 2011-10-18 Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh Patch containing fentanyl
AU2003251482A1 (en) 2002-06-10 2003-12-22 Euro-Celtique, S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
AU2003268144A1 (en) 2002-08-20 2004-03-11 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
AU2002951965A0 (en) 2002-10-09 2002-10-24 Monash University Amidine compounds
TWI296531B (en) 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US20040208917A1 (en) 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
MXPA05011703A (es) 2003-04-30 2006-01-23 Purdue Pharma Lp Forma de dosis transdermica resistente a los retardadores que comprende un componente de agente activo y un componente de agente adverso en el sitio distal de la capa del agente activo.
US20050113365A1 (en) 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
CN100500151C (zh) 2004-04-02 2009-06-17 北京万全阳光医药科技有限公司 一种水溶性药物舌下给药制剂
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US8574604B2 (en) 2005-04-15 2013-11-05 Interface Biologics, Inc. Methods and compositions for the delivery of biologically active agents
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
WO2007052308A2 (en) 2005-11-03 2007-05-10 Brain N' Beyond Biotech Pvt. Ltd. Glyco-phosphorylated biologically active agents
GB0523031D0 (en) 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US8071125B2 (en) 2005-12-09 2011-12-06 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
USD576282S1 (en) 2006-06-16 2008-09-02 Activatek, Inc. Adhesive transdermal medicament patch
USD625017S1 (en) 2006-08-11 2010-10-05 Hisamitsu Pharmaceutical Co., Inc. Medical transdermal patch
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CN100512817C (zh) 2006-11-15 2009-07-15 闫章年 复方噻拉嗪注射液及制备工艺
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
JP2010514789A (ja) 2006-12-27 2010-05-06 アベール ファーマシューティカルズ インコーポレイテッド 副腎皮質ステロイド投与のための経皮的方法及びパッチ
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
WO2009139411A1 (ja) 2008-05-15 2009-11-19 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2298277A1 (en) 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168377A (zh) * 1996-05-28 1997-12-24 东国制药株式会社 新的丁丙诺菲止痛剂同型物
WO2008109156A2 (en) * 2007-03-06 2008-09-12 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A highly selective κ-opioid receptor agonist with low addictive potential and dependence liability;Hee Sock Park，等;《Bioorganic & Medicinal Chemistry Letters》;20060502;第16卷(第3期);第3609-3613页 *
Methylation of the Enolates of Thevinone and some Analogues;Andrew Coop，等;《tetrahedron》;19951231;第51卷(第35期);第9681-9698页 *
Novel Analgesics and Molecular Rearrangements in the Morphine-Thebaine Group. 11. Alcohols Derived from 6,14-endo-Etheno- and 6,14-endo-Ethanotetrahydrothebaine;K. W. Bentley，等;《Journal of the American Chemical Society》;19670621;第89卷(第13期);第3273-3280页 *
Novel Analgesics and Molecular Rearrangements in the Morphine-Thebaine Group. I. Ketones Derived from 6,14-endo-Ethenotetrahydrothebaine;K. W. Bentley，等;《Journal of the American Chemical Society》;19670621;第89卷(第13期);第3267-3273页 *

Also Published As

Publication number Publication date
TW201022274A (en) 2010-06-16
JP2012510985A (ja) 2012-05-17
US20170267687A1 (en) 2017-09-21
CN104119349A (zh) 2014-10-29
JP5787764B2 (ja) 2015-09-30
CN102307877B (zh) 2015-12-16
SI2370443T1 (sl) 2015-12-31
EP2370443B1 (en) 2015-08-05
JP6151307B2 (ja) 2017-06-21
SG171456A1 (en) 2011-07-28
IL213207B (en) 2018-01-31
CN102307877A (zh) 2012-01-04
EP3018133A1 (en) 2016-05-11
CY1116875T1 (el) 2017-04-05
ZA201104161B (en) 2016-05-25
WO2010067101A1 (en) 2010-06-17
AU2009326196A1 (en) 2011-06-23
PT2370443E (pt) 2015-10-23
US9481681B2 (en) 2016-11-01
MY159913A (en) 2017-02-15
AU2009326196A2 (en) 2012-08-30
UY32295A (es) 2010-06-30
DK2370443T3 (en) 2015-11-09
TWI630208B (zh) 2018-07-21
PL2370443T3 (pl) 2016-01-29
HK1161720A1 (en) 2012-08-03
ME02262B (me) 2016-02-29
KR101992272B1 (ko) 2019-06-24
SMT201500273B (it) 2016-01-08
HUE025913T2 (en) 2016-04-28
HRP20151138T1 (hr) 2015-11-20
MX359363B (es) 2018-09-26
PA8852801A1 (es) 2010-04-21
EP2370443A1 (en) 2011-10-05
AR074545A1 (es) 2011-01-26
US9206190B2 (en) 2015-12-08
US20160115174A1 (en) 2016-04-28
TW201531476A (zh) 2015-08-16
ES2548881T3 (es) 2015-10-21
CA2745537A1 (en) 2010-06-17
TWI541246B (zh) 2016-07-11
US20120010231A1 (en) 2012-01-12
US20150133483A1 (en) 2015-05-14
IL213207A0 (en) 2011-07-31
US10745406B2 (en) 2020-08-18
CL2011001363A1 (es) 2011-09-23
EA201170781A1 (ru) 2012-01-30
RS54309B1 (sr) 2016-02-29
EA022210B1 (ru) 2015-11-30
MX2011006095A (es) 2011-09-22
CA2745537C (en) 2017-01-17
KR20110098801A (ko) 2011-09-01
KR20170082665A (ko) 2017-07-14
JP2015157864A (ja) 2015-09-03
NZ593102A (en) 2013-10-25
AU2009326196B2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CN104119349B (zh) 二氢埃托啡及其制备
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
CN102803247A (zh) 组胺h3受体拮抗剂的新颖富马酸盐
US3764684A (en) Novel indolobenzazepine derivatives, useful as tranquilizers
EP0581767B1 (en) 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS
HK1226717A (en) Dihydroetorphines
HK1226717A1 (en) Dihydroetorphines
ES2462756T3 (es) Procedimientos de síntesis de alcaloides opiáceos con formación reducida de impurezas
HK1161720B (en) Dihydroetorphines and their preparation
KR910004449B1 (ko) 인돌 화합물, 이들의 제조방법 및 이들 화합물을 함유하는 약학적 조성물
HU196392B (en) Process for production of benzodioxephane-derivatives and medical preparatives containing them as active substance
WO1994025465A1 (en) SUBSTITUTED METHYLENEDIOXY[3',4':6,7]INDOLIZINO-[1,2-b]QUINOLINONES
CZ20002312A3 (cs) Nová fosfátová sůl izopropylmethyl-[2-(3-npropoxyfenoxy)ethyl]aminu

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170412

CF01 Termination of patent right due to non-payment of annual fee